Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective

Published:2022-10-17 Issue:12 Volume:18 Page:1207-1215
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Suzuki Shigeaki¹^ORCID,Uzawa Akiyuki²,Murai Hiroyuki³

Affiliation:

1. Department of Neurology, Keio University School of Medicine, Tokyo, Japan

2. Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan

3. Department of Neurology, International University of Health and Welfare, Narita, Japan

Funder

JSPS KAKENHI

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2022.2136167

Reference46 articles.

1. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders

2. LRP4-IgG service line testing in seronegative myasthenia gravis and controls

3. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r

4. Japanese clinical guidelines for myasthenia gravis: Putting into practice

5. Health-related quality-of-life and treatment targets in myasthenia gravis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report;BMC Neurology;2024-08-22

2. Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan;Neurology Clinical Practice;2024-06

3. Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control;Biomedicines;2024-05-30

4. Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod;European Journal of Neurology;2024-05-08

5. Efgartigimod in the treatment of Guillain–Barré syndrome;Journal of Neurology;2024-03-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3